Ganciclovir elaidic acid

Drug Profile

Ganciclovir elaidic acid

Alternative Names: P 4018

Latest Information Update: 18 Sep 2001

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Norsk Hydro
  • Developer Nonindustrial source
  • Class Antineoplastics; Antivirals; Hypoxanthines; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Herpesvirus infections

Most Recent Events

  • 18 Sep 2001 P 4018 is now called ganciclovir elaidic acid
  • 18 Sep 2001 No-Development-Reported for Herpesvirus infections in Belgium (Intraperitoneal)
  • 08 Sep 1997 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top